puromycin aminonucleoside has been researched along with Liver Cirrhosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertho-Ruault, C; de Gouville, AC; Gellibert, F; Grygielko, ET; Huet, S; Laping, NJ; Mathews, N; Nguyen, VL; Patikis, A; Woolven, J | 1 |
1 other study(ies) available for puromycin aminonucleoside and Liver Cirrhosis
| Article | Year |
|---|---|
Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Topics: Activin Receptors, Type I; Acute Disease; Administration, Oral; Animals; Benzamides; Collagen Type I; Collagen Type I, alpha 1 Chain; Dimethylnitrosamine; Fibrosis; Kidney; Liver Cirrhosis; Male; Models, Molecular; Protein Serine-Threonine Kinases; Puromycin Aminonucleoside; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; RNA, Messenger; Structure-Activity Relationship | 2006 |